Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors

Oncogene

Volumn 27, Issue 6, 2008, Pages 775-782

  Nardi, V ^a   Raz, T ^a   Cao, X ^b   Wu, C J ^c   Stone, R M ^c   Cortes, J ^d   Deininger, M W N ^e   Church, G ^f   Zhu, J ^b   Daley, G Q ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Drug resistance; Mutations detection; Solid phase PCR

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

ANIMAL CELL; ARTICLE; BIOASSAY; BIOLOGICAL MONITORING; BLOOD ANALYSIS; CANCER RESISTANCE; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; LEUKEMIA RELAPSE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; POINT MUTATION; POLYMERASE COLONY ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 38749145172     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210698     Document Type: Article

References (21)

1. Azam M, Latek RR, Daley GQ. (2003). Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843.
2. Azam M, Nardi V, Shakespeare WC, Metcalf III CA, Bohacek RS, Wang Y et al. (2006). Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 103: 9244-9249.
3. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F. et al. (2006). Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood 108: 1809-1820.
4. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. (2006). Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitro-sourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108: 2332-2338.
5. Butz J, Wickstrom E, Edwards J. (2003). Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. BMC Biotechnol 3: 11.
6. Daley GQ, Van Etten RA, Baltimore D. (1990). Induction of chronic myelogenous leukemia in mice by the P210BCR/ABL gene of the Philadelphia chromosome. Science 247: 824-830.
7. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. (2006). BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 3: 551-559.
8. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J. et al. (2006). Monitoring CML patients responding to treatment withtyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28-37.
9. Kang HY, Hwang JY, Kim SH, Goh HG, Kim M, Kim DW. (2006). Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 91: 659-662.
10. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G. et al. (2006). Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 18: 18.
11. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. (2006). BEAMing up for detection and quantification of rare sequence variants. Nat Methods 3: 95-97.
12. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA et al. (2005). Genome sequencing in micro-fabricated high-density picolitre reactors. Nature 437: 376-380.
13. Mitra RD, Church GM. (1999). In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res 27: e34.
14. Mitra RD, Butty VL, Shendure J, Williams BR, Housman DE, Church GM. (2003). Digital genotyping and haplotyping withpolymerase colonies. Proc Natl Acad Sci USA 100: 5926-5931.
15. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F et al. (2007). Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109: 497-499.
16. Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G et al. (2004). Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 50: 1205-1213.
17. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R. et al. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541.
18. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y et al. (2006). Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12: 852-855.
19. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D. et al. (2005). High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation withclonal cytogenetic evolution but not response to therapy. Blood 106: 2128-2137.
20. Zhang K, Zhu J, Shendure J, Porreca GJ, Aach JD, Mitra RD. et al. (2006). Long-range polony haplotyping of individual human chromosome molecules. Nat Genet 38: 382-387.
21. Zhu J, Shendure J, Mitra RD, Church GM. (2003). Single molecule profiling of alternative pre-mRNA splicing. Science 301: 836-838.